Class information for:
Level 1: ADVANCED PANCREATIC CANCER//FOLFIRINOX//METASTATIC PANCREATIC CANCER

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
4721 1663 43.9 81%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
394 16254 PANCREATIC CANCER//PANCREATICODUODENECTOMY//PANCREATIC FISTULA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ADVANCED PANCREATIC CANCER Author keyword 29 58% 2% 33
2 FOLFIRINOX Author keyword 18 57% 1% 21
3 METASTATIC PANCREATIC CANCER Author keyword 18 67% 1% 16
4 GEMCITABINE REFRACTORY Author keyword 15 82% 1% 9
5 ADVANCED PANCREATIC CARCINOMA Author keyword 7 53% 1% 9
6 GASTROENTEROL ENDOCRINOL INFECTIOL METAB Address 6 80% 0% 4
7 PEFG REGIMEN Author keyword 6 80% 0% 4
8 SOL GOLDMAN PANCREAT CANC Address 6 11% 3% 46
9 FIXED DOSE RATE INFUSION Author keyword 5 63% 0% 5
10 KRASG12D Author keyword 4 67% 0% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ADVANCED PANCREATIC CANCER 29 58% 2% 33 Search ADVANCED+PANCREATIC+CANCER Search ADVANCED+PANCREATIC+CANCER
2 FOLFIRINOX 18 57% 1% 21 Search FOLFIRINOX Search FOLFIRINOX
3 METASTATIC PANCREATIC CANCER 18 67% 1% 16 Search METASTATIC+PANCREATIC+CANCER Search METASTATIC+PANCREATIC+CANCER
4 GEMCITABINE REFRACTORY 15 82% 1% 9 Search GEMCITABINE+REFRACTORY Search GEMCITABINE+REFRACTORY
5 ADVANCED PANCREATIC CARCINOMA 7 53% 1% 9 Search ADVANCED+PANCREATIC+CARCINOMA Search ADVANCED+PANCREATIC+CARCINOMA
6 PEFG REGIMEN 6 80% 0% 4 Search PEFG+REGIMEN Search PEFG+REGIMEN
7 FIXED DOSE RATE INFUSION 5 63% 0% 5 Search FIXED+DOSE+RATE+INFUSION Search FIXED+DOSE+RATE+INFUSION
8 KRASG12D 4 67% 0% 4 Search KRASG12D Search KRASG12D
9 METASTATIC PANCREATIC ADENOCARCINOMA 4 75% 0% 3 Search METASTATIC+PANCREATIC+ADENOCARCINOMA Search METASTATIC+PANCREATIC+ADENOCARCINOMA
10 NAB PACLITAXEL 4 15% 1% 23 Search NAB+PACLITAXEL Search NAB+PACLITAXEL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PLUS GEMCITABINE 77 40% 9% 151
2 GEMCITABINE PLUS PLACEBO 53 85% 2% 28
3 DUCTAL ADENOCARCINOMA 38 12% 17% 285
4 COMPARING GEMCITABINE 38 76% 2% 26
5 GEMCITABINE PRETREATED PATIENTS 20 100% 1% 9
6 DOSE RATE INFUSION 19 51% 2% 27
7 ONCOGENIC KRAS 19 38% 2% 39
8 ADVANCED ADENOCARCINOMA 17 46% 2% 28
9 GISCAD 12 86% 0% 6
10 TRACT CANCER GISCAD 12 86% 0% 6

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Pancreatic Cancer 2010 726 81 26%
Pancreatic Adenocarcinoma 2014 32 69 38%
Advanced pancreatic carcinoma: current treatment and future challenges 2010 213 59 49%
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis 2014 12 33 73%
Oncogenic KRAS signalling in pancreatic cancer 2014 19 51 43%
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies 2014 20 69 41%
Therapeutic Advances in Pancreatic Cancer 2013 66 75 36%
Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy 2009 62 20 95%
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review) 2010 54 92 88%
Systemic treatment of advanced pancreatic cancer 2012 34 66 71%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 GASTROENTEROL ENDOCRINOL INFECTIOL METAB 6 80% 0.2% 4
2 SOL GOLDMAN PANCREAT CANC 6 11% 2.8% 46
3 HEPATOBILIARY PANCREAT ONCOL 4 13% 1.7% 29
4 WEST SCOTLAND PANCREAT UNIT 4 36% 0.5% 8
5 UNIT 953 3 57% 0.2% 4
6 NORRIS COTTON COMPREHENS CANC 3 45% 0.3% 5
7 MED KLIN POLIKLIN MS HAMATOL ONKOL 3 50% 0.2% 4
8 WOLFSON WOHL CANC 2 20% 0.6% 10
9 ABT CHIRURG ONKOL 2 67% 0.1% 2
10 CCC NORTH 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000215933 PANCREATIC CANCER//BORDERLINE RESECTABLE//LOCALLY ADVANCED PANCREATIC CANCER
2 0.0000191648 PANCREATIC JUICE//K RAS POINT MUTATION//K RAS MUTATION
3 0.0000126800 GEMCITABINE//TROXACITABINE//DEOXYCYTIDINE KINASE
4 0.0000102396 PANCREATIC STELLATE CELLS//PANCREATIC FIBROSIS//PANCREATIC STELLATE CELL
5 0.0000079274 FAMILIAL PANCREATIC CANCER//CLIN MOL EPIDEMIOL CANC UNIT//PANCREATIC CANCER SUSCEPTIBILITY
6 0.0000059027 CA 19 9//CA19 9//SPAN 1
7 0.0000057212 FP3//HOLLOW FIBRE ASSAY//AFFILIATED ZHUJI HOSP
8 0.0000043695 ADVANCED GASTRIC CANCER//S 1//METASTATIC GASTRIC CANCER
9 0.0000037792 NIMOTUZUMAB//H R3//CETUXIMAB
10 0.0000034216 BIOCHEMICAL MODULATION//LEUCOVORIN//FOLINIC ACID